Press releases
- CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
- Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
- Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³
Key statistics
SmartText not available for this item.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3,635.42 |
---|---|
High | 3,635.42 |
Low | 3,635.42 |
Bid | -- |
Offer | -- |
Previous close | 3,635.42 |
Average volume | -- |
---|---|
Shares outstanding | 483.25m |
Free float | 481.01m |
P/E (TTM) | 35.47 |
Market cap | 133.28bn AUD |
EPS (TTM) | 7.78 AUD |
Annual div (ADY) | 41.28 MXN |
---|---|
Annual div yield (ADY) | -- |
Div ex-date | Sep 11 2023 |
Div pay-date | Oct 04 2023 |
Data delayed at least 20 minutes, as of Jan 10 2023 11:30 GMT.
More ▼